Increasing the use of 3GIRS products in Insecticide Resistance Management (IRM) programmes.
NgenIRS stands for Next Generation IRS. It is a Unitaid-funded initiative to expand the use of new anti-malarial insecticides to maintain the important role of mosquito control in combating malaria.
Managing insecticide resistance is one of the most important challenges malaria control programmes face. On 1st February 2016, representatives from Unitaid and IVCC met in Geneva to sign a contract for the NgenIRS project. The project employs a series of market interventions to address the factors hindering wide-scale use of new, longer lasting resistance breaking insecticides (eg high prices, limited completion, small and volatile market and lack of evidence of cost effectiveness). This long anticipated event was the culmination of two years of co-development of the project concept and negotiations between IVCC and Unitaid.
The $65.1 million initiative supports countries in obtaining new and effective insecticides at lower prices to spray walls in homes and fight growing insecticide resistance. Over four years, the project aims to protect at least 50 million people from malaria across Africa. Despite its effectiveness in combating malaria, indoor spraying of walls has fallen by 40 per cent in the past four years due to increased resistance to older products and higher cost of new alternatives.
Unitaid and IVCC have teamed up with the President’s Malaria Initiative (PMI), Abt Associates, PATH and The Global Fund to work with industry and country malaria-control programmes to make alternative insecticides with high efficacy more readily available in countries with a high burden of malaria. The initiative will use a co-payment from Unitaid to bring down the price of these new and more effective products in the short term. A further aim is to reduce the cost of procuring products in the long term through improved forecasting and increased competition among manufacturers.
Unitaid is engaged in finding new ways to prevent, treat and diagnose HIV/AIDS, tuberculosis and malaria more quickly, more cheaply and more effectively. It takes game-changing ideas and turns them into practical solutions that can help accelerate the end of the three diseases. Established in 2006 by Brazil, Chile, France, Norway and the United Kingdom, Unitaid plays an important part in the global effort to defeat HIV/AIDS, tuberculosis and malaria.